Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.

Immunotherapy is increasingly becoming standard therapy in cancer, with technology, such as checkpoint inhibitors and cell therapy, raising the efficacy bar in many forms of the disease. But the ...

Viper” to its crews—started as a nimble, low-cost day fighter and became the backbone of Western airpower. -The U.S. military ...

Omeros' stock surged over 150% after licensing zaltenibart to Novo Nordisk for $240M upfront, plus milestones and royalties.

A pilot project in Maryland is using EVs to create a cleaner, more resilient, and more affordable energy supply.

Economical, adaptable and built in Australia over months, not years – deploying ASVs at scale would significantly boost the ...

Trent Frederic getting a turn on Edmonton’s top line with Connor McDavid and Leon Draisaitl is one of the more ...

In recent years, a unique profession, the doula service, has begun to gain popularity around the world, gradually reaching ...

Valdez ‘VJ’ Edgecombe and the Philadelphia 76ers will play their final preseason game tonight, and then it’s on to games that matter, for one of The Bahamas’ most anticipated regular ...

Gayle moved to Crystal Palace for £6 million at the end of the season before signing for Newcastle United for £10 million. He ...

North Shore Uranium Ltd. (TSXV:NSU) ("North Shore" or the "Company") is pleased to announce the completion of a prospecting ...

In a week when worries over US-China trade tensions once again foist themselves on investors, the efforts by various parties ...